Get started
Author

Sascha Troschke‐Meurer

Observed names: S Troschke-Meurer, S. Troschke-Meurer, Sascha Troschke-Meurer, Troschke-Meurer, Sascha
ORCID: 0000-0002-6185-462X
Observed ORCID: 0000-0002-6185-462X
OpenAlex ID: A5043909136
PD-1 blockade augments anti-neuroblastoma immune response induced by anti-GD 2 antibody ch14.18/CHO
2017 · Nikolai Siebert, Maxi Zumpe, et al. · OncoImmunology · 71
PDF
Neuroblastoma patients with high-affinity FCGR2A, -3A and stimulatory KIR 2DS2 treated by long-term infusion of anti-GD2 antibody ch14.18/CHO show higher ADCC levels and improved event-free survival
2016 · Nikolai Siebert, Christian Jensen, et al. · OncoImmunology · 56
PDF
Implementation of a combined CDK inhibition and arginine-deprivation approach to target arginine-auxotrophic glioblastoma multiforme cells
2022 · Christin Riess, Katharina del Moral, et al. · Cell Death and Disease · 30
PDF
Long-term, continuous infusion of single-agent dinutuximab beta for relapsed/refractory neuroblastoma: an open-label, single-arm, Phase 2 study
2023 · Holger N. Lode, Karoline Ehlert, et al. · British Journal of Cancer · 29
PDF
GD2 targeting by dinutuximab beta is a promising immunotherapeutic approach against malignant glioma
2020 · Sascha Marx, Fabian Wilken, et al. · Journal of Neuro-Oncology · 23
Randomized use of anti-GD2 antibody dinutuximab beta (DB) long-term infusion with and without subcutaneous interleukin-2 (scIL-2) in high-risk neuroblastoma patients with relapsed and refractory disease: Results from the SIOPEN LTI-trial.
2019 · Holger N. Lode, Dominique Valteau-Couanet, et al. · Journal of Clinical Oncology · 23
Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEN Phase 2 Trial
2018 · Nikolai Siebert, Sascha Troschke-Meurer, et al. · Cancers · 22
PDF
Immunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation and Subsequent GD2 (ch14.18/CHO) Antibody Treatment
2021 · Christian Martin Seitz, Tim Flaadt, et al. · Frontiers in Immunology · 21
PDF
Low CD4⁺/CD25⁺/CD127⁻ regulatory T cell- and high INF-γ levels are associated with improved survival of neuroblastoma patients treated with long-term infusion of ch14.18/CHO combined with interleukin-2
2019 · Sascha Troschke-Meurer, Nikolai Siebert, et al. · OncoImmunology · 20
Combined inhibition of EZH2 and CDK4/6 perturbs endoplasmic reticulum-mitochondrial homeostasis and increases antitumor activity against glioblastoma
2024 · Thomas Freitag, Philipp Kaps, et al. · npj Precision Oncology · 19
PDF
Combined Blockade of TIGIT and PD-L1 Enhances Anti-Neuroblastoma Efficacy of GD2-Directed Immunotherapy with Dinutuximab Beta
2023 · Nikolai Siebert, Maxi Zumpe, et al. · Cancers · 19
PDF
Inflammatory response and treatment tolerance of long‐term infusion of the anti‐GD2 antibody ch14.18/CHO in combination with interleukin‐2 in patients with high‐risk neuroblastoma
2018 · Kiraz Ceylan, Luciana J. Jahns, et al. · Pediatric Blood & Cancer · 17
Chemotherapeutics Used for High-Risk Neuroblastoma Therapy Improve the Efficacy of Anti-GD2 Antibody Dinutuximab Beta in Preclinical Spheroid Models
2023 · Sascha Troschke-Meurer, Maxi Zumpe, et al. · Cancers · 16
PDF
BCL11B depletion induces the development of highly cytotoxic innate T cells out of IL-15 stimulated peripheral blood αβ CD8+ T cells
2022 · Hannes Forkel, Piotr Grabarczyk, et al. · OncoImmunology · 12
Impact of IL-2 on Treatment Tolerance in Patients With High-Risk Neuroblastoma Treated With Dinutuximab Beta-Based Immunotherapy
2020 · Filiz Cicek, Sascha Troschke-Meurer, et al. · Frontiers in Pediatrics · 11
PDF
Effect and Tolerance of N5 and N6 Chemotherapy Cycles in Combination with Dinutuximab Beta in Relapsed High-Risk Neuroblastoma Patients Who Failed at Least One Second-Line Therapy
2023 · Holger N. Lode, Ruth Ladenstein, et al. · Cancers · 10
PDF
Immune Response and Outcome of High-Risk Neuroblastoma Patients Immunized with Anti-Idiotypic Antibody Ganglidiomab: Results from Compassionate-Use Treatments
2022 · Leah Klingel, Nikolai Siebert, et al. · Cancers · 10
PDF
The Immunocytokine FAP-IL-2v Enhances Anti-Neuroblastoma Efficacy of the Anti-GD2 Antibody Dinutuximab Beta
2022 · Nikolai Siebert, Justus Leopold, et al. · Cancers · 10
PDF
Reduction of CD11b + myeloid suppressive cells augments anti-neuroblastoma immune response induced by the anti-GD 2 antibody ch14.18/CHO
2020 · Nikolai Siebert, Maxi Zumpe, et al. · OncoImmunology · 10
Co-expression of IL-15 enhances anti-neuroblastoma effectivity of a tyrosine hydroxylase-directed DNA vaccination in mice
2018 · Madlen Marx, Maxi Zumpe, et al. · PLoS ONE · 6
PDF
Correlation of killer-cell Ig-like receptor (KIR) haplotypes and Fcγ-receptor polymorphisms with survival of high-risk relapsed/refractory neuroblastoma patients treated by long-term infusion of anti-GD2 antibody ch14.18/CHO.
2016 · Holger N. Lode, Sascha Troschke-Meurer, et al. · Journal of Clinical Oncology · 5
Dinutuximab Beta Versus Naxitamab in the Treatment of Relapsed/Refractory Neuroblastoma in Patients with Stable Disease, Minor Response or Partial Response and Disease in Bone or Bone Marrow: Systematic Review and Matching-Adjusted Indirect Comparison
2025 · Holger N. Lode, Przemysław Holko, et al. · Cancers · 4
PDF
Phase II clinical trial with long-term infusion of anti-GD2 antibody ch14.18/CHO in combination with interleukin-2 (IL2) in patients with high risk neuroblastoma.
2016 · Holger N. Lode, Dominique Valteau-Couanet, et al. · Journal of Clinical Oncology · 4
Exploring the dual role of extracellular vesicles in coagulation and immune modulation in glioblastoma
2026 · Annabell Wolff, Grit Waitz, et al. · Scientific Reports · 3
PDF
CDK inhibitors promote neuroblastoma cell differentiation and increase sensitivity to retinoic acid—a promising combination strategy for therapeutic intervention
2025 · Olia Shokraie, Larissa Lechermeier, et al. · Cell Death Discovery · 3
PDF
Works count: 64
Citation count: 470
H-index: 13
I10-index: 19
Year
Topic
Type